Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 11, 2011, Pages

  Chen, Hengxi ^a   Li, Jinke ^a   Cui, Tao ^a   Hu, Lina ^b  

^a SICHUAN UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSERELIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ESTRADIOL; ETOPOSIDE; FLUOROURACIL; FOLLITROPIN; GONADORELIN DERIVATIVE; GOSERELIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; PLACEBO; PREDNISONE; PROCARBAZINE; TRIPTORELIN; VINBLASTINE; VINCRISTINE; DRUG DERIVATIVE; GONADORELIN;

ADJUVANT THERAPY; AMENORRHEA; ANTRAL FOLLICLE COUNT; DATA ANALYSIS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ECHOGRAPHY; FEMALE; HUMAN; MENSTRUATION; META ANALYSIS; OVULATION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MENSTRUATION; OVULATION; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860793213     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008018.pub2     Document Type: Review

References (71)

1. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertility and Sterility 2009;91:694-7.
2. Gilanni MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pacific Journal of Clinical Oncology 2007;3:79-83.
3. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7.
4. Waxman JH, Ahmed R, Smith D, Wrigley PFM, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemotherapy and Pharmacology 1987;19:159-62.
5. Azem F, Samara N, Cohen T, Ben-Yosef D, Almog B, Lessing JB, et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease. Journal of Assisted Reproduction and Genetics 2008;25(11-12):535-8.
6. Bernhard Jurg, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients- the international breast cancer study group trial VIII. Journal of Clinical Oncology 2007;25:263-70.
7. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2009;9:401-5.
8. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy induced gonadotoxicity in young women by GnRH-a. Journal of National Cancer Institute Monographs 2005;34:40-3.
9. Blumenfeld Z, Avivi I, Eckman A, Epelbaum Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertility and Sterility 2008;89:166-73.
10. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martinez de Osaba M, Balash J. Use of gonadotropin releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertility and Sterility 2007;87:703-6.
11. Dann EJ, Epelbaum R, Avivi I. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Human Reproduction 2005;20:2247-9.
12. Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Annals of Oncology 2006;17(1):74-8.
13. Falorio S, Angrilli F, Fioritoni G. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma. Leukemia and Lymphoma 2008;49:1087-93.
14. Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecological Endocrinology 2005;20:274-8.
15. Pereyra Pacheco B, Mendez Ribas JM, Milone G. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecologic Oncology 2001;81:391-7.
16. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A. Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106(3):514-23.
17. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and Rheumatism 2005;52:2761-7.
18. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith I. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Research and Treatment 2008;110(3):411-6.
19. Behringer K, Wildt L, Haverkamp H, Diehl V, Pfistner B, Engert A. Results of the randomised phase II. for the reduction of ovarian failure with use GnRH-analogues and oral contraceptives in young women (18-40 years) treated with intensive chemotherapy for advanced-stage Hodgkin lymphoma (HL). Haematologia 2007;92(Suppl 5):63-4.
20. Ismail KR, Minton S, Cox C, Sims I, Lacevic M, Gross KM, et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology: ASCO annual meeting proceedings. 2008; Vol. 26:12.
21. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Research and Treatment 2009;117(3):561-7.
22. Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmunity Reviews 2006;5:269-72.
23. Munster PN. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology: ASCO annual meeting proceedings 2008; Vol. 26.
24. Ataya M, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Research 1985;45:3651-6.
25. Ataya K, Moghissi K. Chemotherapy-induced premature ovarian failure: mechanisms and prevention. Steroids 1989;54:607-26.
26. Ataya K, Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reproductive Toxicology 1993;7:229-35.
27. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biology of Reproduction 1995;52:365-72.
28. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. A report from the German Hodgkin's Lymphoma StudyGroup. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen and the use of oral contraceptives during therapy. Journal of Clinical Oncology 2005;23:7555-64.
29. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1996;14:1718-29.
30. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Human Reproduction 1996;11(8):1620-6.
31. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. Journal of the Society for Gynecologic Investigation 1999;6:229-39.
32. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embrya, oocytes, or ovaries. The Oncologist 2007;12:1044-54.
33. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertility and Sterility 2008;89:166-73.
34. Blumenfeld Z, Von WolffM. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update 2008;14:543-52.
35. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophospamide-induced gonadotoxicity in female rats. British Journal of Cancer 1990;61:861-5.
36. Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, et al. Evidence of castration mediate effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. Journal of Clinical Oncology 1987;5:1771-8.
37. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long-term survivors of cancer during adolescence. American Journal of Obstetrics and Gynecology 1992;166:788-93.
38. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin's disease. JAMA 1979;242:1877-81.
39. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. American Journal of Epidemiology 1999;150:245-54.
40. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. Journal of Women's Health 2009;18(3):311-9.
41. Couzinet B, Lahlou N, Thomas G, Thalabard JC, Bouchard P, Roger M, et al. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women. Clinical Endocrinology 1991;34:477-83.
42. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertility and Sterility 2005;83:1333-8.
43. De Koning CH, Popp-Snijders C, Schoemaker J, Lambalk CB. Elevated FSH concentrations in imminent ovarian failure are associated with higher FSH and LH pulse amplitude and response to GnRH. Human Reproduction 2000;15(7):1452-6.
44. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics and Gynecology 2005;17:21-6.
45. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1:1132-4.
46. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Annals of Oncology 1990;1:183-8.
47. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology 1999;17:2365-70.
48. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertility and Sterility 2005;83(2):291-330.
49. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
50. Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Human Reproduction 2008;23:863-8.
51. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecologic and Obstetric Investigation 2007;63:102-6.
52. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-9.
53. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy forHodgkin's disease. Journal of Cancer Research and Clinical Oncology 1987;113:260-6.
54. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. The Journal of Clinical Endocrinology and Metabolism 2003;88(11):5307-14.
55. Luborsky J, Llanes B, Roussev R, Coulam C. Ovarian antibodies, FSH and inhibin B: Independent markers associated with unexplained infertility. Human Reproduction 2000;15(5):1046-51.
56. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update 2005;11:69-89.
57. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. European Journal of Gynaecological Oncology 2004;25:90-2.
58. Matikainen T, Ding YQ, Vergara M, Huhtainiemi I, Couzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone antagonist and agonist treatments in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75:820-5.
59. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Human Reproduction 1999;14:1903-7.
60. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Human Reproduction Update 2001;7:535-43.
61. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Human Reproduction 2004;19(6):1294-9.
62. Moore HC. Following treatment for breast cancer. The incidence of treatment-related amenorrhea is related to patient age and to the treatment regimen. Current Oncology Reports 2000;2:587-93.
63. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Standord experience. International Journal of Radiation Oncology, Biology, Physics 1990;19:873-80.
64. Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX. Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats. Zhonghua Fu Chan Ke Za Zhi 2007;42:546-50.
65. Rabinovici J, Rothman P, Monroe SE, Nerenberg C, Jaffe RB. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75:1220-5.
66. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
67. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-5.
68. Shelling AN, Burton KA, Chand AL, Van Ee CC, France JT, Farquhar CM, et al. Inhibin: a candidate gene for premature ovarian failure. Human Reproduction 2000;15(12):2644-9.
69. Sobrinho LG, Levine RA, DeConti RC. Amenorrhea inpatients with Hodgkin's disease treated with anti-neoplastic agents. Amarican Journal of Obstetric and Gynecology 1971;109:135-9.
70. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetric and Gynecology 2003;101:251-7.
71. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. New England Journal of Medicine 1973;289:1159-62.